Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 14/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3552427 | 0.87 | MAPK14 (0.35) | PARP1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3208065 | 0.84 | CNR2 (0.34) | PARP1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3241618 | 0.82 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3217290 | 0.80 | MAPK14 (0.33) | MAPK14 | |
| SCHEMBL3209839 | 0.79 | MAPK14 (0.44) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3543835 | 0.78 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3547183 | 0.78 | MAPK14 (0.31) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3545113 | 0.78 | PARP1 (0.37) | PARP1CNR2SMN1; SMN2RORC | |
| SCHEMBL13495559 | 0.77 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3552679 | 0.76 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010019930-A1 | UREA DERIVATIVES AS INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | MAP4K2, MAP3K1, MAP3K20 | PARP1 2990/4885MAPK14 33/4885MAPK13 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.